[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jacques E. Chelly\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":97},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100426740","auriculotherapy-in-the-treatment-of-pre-operative-anxiety-100426740",false,"NCT04836936","Auriculotherapy in the Treatment of Pre-Operative Anxiety","Auriculotherapy in the Treatment of Pre-Operative Anxiety - A Randomized, Prospective, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Greater than 18 years of age\n* Scheduled to undergo partial or full elective nephrectomy\n* Subject is willing and able to provide informed consent\n* Anxiety score ≥ 19 and ≤ 29 on the PROMIS Emotional Distress-Anxiety-Short Form 8a.\n\nExclusion Criteria:\n\n* Opioid dependence, based on the DSM definition of Opioid Use Disorder (OUD)\n* Chronic pain condition where daily opioid use is needed\n* History of fibromyalgia\n* Anatomical malformation of ear (genetic or trauma-induced)\n* Vasculopathy of ear\n* Raynaud's disease\n* Patient Refusal",true,"ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to use the validated PROMIS Emotional Distress - Anxiety - Short Form 8a and PROMIS Emotional Distress-Depression-Short Form pre-and post-intervention to establish a superior correlation between the auriculotherapy treatment and the reduction of perioperative anxiety. Subject population will include those having a partial or total nephrectomy for cancer. Drawing the role that auriculotherapy may play in reducing perioperative anxiety related requirement after surgery may also help in reducing the risk of opioid use disorders (OUD) since anxiety has been found to be a major risk factor for OUD in surgical patients. Therefore, this trial will also examine the effect of the auriculotherapy intervention in reducing opioid requirement after surgery.",[27],"Anxiety Preoperative",[29,30],"Nephrectomy","Auriculotherapy","RECRUITING","2026-06-02",{"date":34,"type":35},"2026-06-03","ACTUAL",{"date":37,"type":35},"2021-04-13",{"date":39,"type":21},"2026-06-30",{"name":41,"class":42},"Jacques E. Chelly","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":5},"100626748","neurocuple-as-an-opioid-alternative-following-total-knee-arthroplasty-100626748","NCT07439666","NEUROCUPLE™ as an Opioid Alternative Following Total Knee Arthroplasty","The Role of NEUROCUPLE™ as an Alternative to Opioids Following Total Knee Arthroplasty Patients","Inclusion Criteria:\n\n* \\>18 years of age\n* Scheduled for elective primary unilateral TKA\n\nExclusion Criteria:\n\n* Children (\\\u003C18 yr.)\n* Pregnant women\n* Active alcoholism (defined as daily use of more than 1 liter of wine and \u002For 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)\n* Severe chronic pain condition that requires daily preoperative opioid dependence\n* Other concomitant surgery being performed in addition to TKA\n* Patients undergoing bilateral TKA\n* Patients undergoing knee replacement revision\n* Patients with limited mobility (in a wheelchair or requiring a walker)\n* Patients who are not returning home after surgery",{"count":52,"type":21},274,[24],"The goal of this clinical trial is to learn if the NEUROCUPLE device can reduce pain and opioid use after primary unilateral total knee arthroplasty (TKA) in adults.\n\nThe main questions it aims to answer are:\n\n* Does the NEUROCUPLE device reduce postoperative pain at rest during the first 24 hours after TKA?\n* Does the NEUROCUPLE device reduce opioid consumption during the first 24 hours after TKA?\n\nResearchers will compare the NEUROCUPLE device to a placebo device (identical in appearance but inactive) to see if the device reduces pain and opioid use after surgery.\n\nParticipants will:\n\n* Apply the NEUROCUPLE device or placebo device for 7 days following surgery\n* Have their pain and opioid use monitored through clinical records and patient reporting\n* Report pain at rest and during movement on postoperative Days 2 and 7\n* Be assessed for nausea, vomiting, device-related side effects, length of hospital stay, and overall satisfaction",[56,57],"Total Knee Arthroplasty Postoperative Pain","Opioid Reduction After TKA",[59,60,61,62,63,64,65,66,67],"Total Knee Arthroplasty","Postoperative Pain","TKA","Opioid Use","Non opioid Pain Management","NEUROCUPLE Patch","Knee Replacement","Acute Postoperative Pain","Randomized Clinical Trial","NOT_YET_RECRUITING","2026-04-02",{"date":71,"type":35},"2026-04-08",{"date":73,"type":21},"2026-05",{"date":75,"type":21},"2027-11",{"name":41,"class":42},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100565944","vagal-stimulator-to-reduce-nasogastric-tube-use-100565944","NCT06648759","Vagal Stimulator to Reduce Nasogastric Tube Use","The Role of a Vagal Stimulator to Reduce the Frequency and Duration on Nasogastric Tube Following Abdominal Surgery","Inclusion Criteria:\n\n* Adults (18 and older) undergoing laparoscopic or open colorectal surgery, or any major abdominal surgeries at UPMC Shadyside\n* Development of post-operative ileus\n* Anticipation of a nasogastric (ng) tube being placed\n\nExclusion Criteria:\n\n* Pregnant subjects\n* Subjects who are unable to read, write, or speak English fluently\n* Subjects who have a developmental or neurological disorder and are not cognitively able to provide consent",{"count":20,"type":21},[24],"Abdominal surgery, laparoscopic or open, is frequently performed at UPMC Shadyside hospital. One of the most frequent complications following abdominal surgery is a postoperative ileus. Although postoperative ileus may be the result of obstruction or leakage, in most cases postoperative ileus (POI) is the result of local irritation because of fluid overload, exogenous opioids, neurohormonal dysfunction, gastrointestinal stretch, local bleeding and inflammation. POI usually lasts between 2 to 7 days. In most cases, a nasogastric tube (NG tube) is used to relieve that gastric pressure until the resolution of the POI. The placement of a NG tube can lead to a local trauma, bleeding and pain. Pain represents a major complaint among those with POI, often contributing to prolonged hospital stays.",[88],"Nasogastric Tube Intubation","2025-12-11",{"date":91,"type":35},"2025-12-17",{"date":93,"type":35},"2024-12-04",{"date":95,"type":21},"2026-09-30",{"name":41,"class":42},""]